PD-1 expression is linked to NK cell dysfunction and advanced liver fibrosis in HIV/HCV-coinfected individuals

被引：0
|
作者：
Polo, M. L. [1 ]
Urioste, A. [1 ]
Gonzalez Polo, V. [1 ]
Poblete, G. [2 ]
Martinez, A. [2 ]
Sisto, A. [2 ]
Rolon, M. J. [2 ]
Turk, G. [1 ]
Laufer, N. [1 ,2 ]
机构：
[1] INBIRS UBA CONICET, Buenos Aires, DF, Argentina
[2] Hosp Fernandez, Buenos Aires, DF, Argentina
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
PDA0102
引用
收藏
页码：104 / 104
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders
    Milazzo, Laura
    Cattaneo, Dario
    Calvi, Elisa
    Gervasoni, Cristina
    Mazzali, Cristina
    Ronzi, Paola
    Peri, Anna Maria
    Ridolfo, Anna Lisa
    D'Avolio, Antonio
    Antinori, Spinello
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (05) : 545 - 549
  • [22] Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis
    Berenguer, Juan
    Aldamiz-Echevarria, Teresa
    Hontanon, Victor
    Fanciulli, Chiara
    Quereda, Carmen
    Busca, Carmen
    Dominguez, Lourdes
    Hernandez, Cristina
    Vergas, Jorge
    Gaspar, Gabriel
    Garcia-Fraile, Lucio J.
    Diez, Cristina
    De Miguel, Marta
    Bellon, Jose M.
    Banares, Rafael
    Gonzalez-Garcia, Juan
    HEPATOLOGY, 2025, 81 (01) : 238 - 253
  • [23] Evolution of liver fibrosis in HIV/HCV-coinfected patients: impact of anti-HCV therapy in patients with different grades of liver stiffness
    Merli, Marco
    Carbone, Alessia
    Messina, Emanuela
    Galli, Laura
    Bagaglio, Sabrina
    Morsica, Giulia
    Gallotta, Giulia
    Lazzarin, Adriano
    Uberti-Foppa, Caterina
    Hasson, Hamid
    HEPATOLOGY, 2012, 56 : 1031A - 1031A
  • [24] Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis
    Berenguer, Juan
    Bellon, Jose M.
    Banares, Rafael
    Gonzalez-Garcia, Juan
    HEPATOLOGY, 2025, 81 (01) : E6 - E7
  • [25] Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)
    Hernandez-Novoa, Beatriz
    Moreno, Ana
    Perez-Elias, Maria J.
    Quereda, Carmen
    Dronda, Fernando
    Casado, Jose L.
    Madrid-Elena, Nadia
    Aguilar, Monica
    Fumero, Emilio
    Molto, Jose
    Moreno, Santiago
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (02) : 471 - 475
  • [26] Rates of liver fibrosis assessment and treatment initiation with IFN-free regimens within a screening program for advanced liver fibrosis among HIV/HCV-coinfected patients
    Mandorfer, Mattias
    Chromy, David
    Strassl, Robert
    Schwabl, Philipp
    Steiner, Sebastian
    Scheiner, Bernhard
    Aichelburg, Maximilian C.
    Grabmeier-Pfistershammer, Katharina
    Rieger, Armin
    Trauner, Michael
    Peck-Radosavljevic, Markus
    Reiberger, Thomas
    HEPATOLOGY, 2015, 62 : 488A - 489A
  • [27] European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain
    Tabernilla, Andres
    Rego-Perez, Ignacio
    Grandal, Marta
    Pernas, Berta
    Pertega, Sonia
    Delgado, Manuel
    Marino, Ana
    Alvarez, Hortensia
    Mena, Alvaro
    Rodriguez-Osorio, Iria
    Domingo Pedreira, Jose
    Javier Blanco, Francisco
    Poveda, Eva
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 73 (02) : 149 - 153
  • [28] Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy
    Labarga, P.
    Fernandez-Montero, J. V.
    Barreiro, P.
    Pinilla, J.
    Vispo, E.
    de Mendoza, C.
    Plaza, Z.
    Soriano, V.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (07) : 475 - 479
  • [29] Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?
    van Santen, Daniela
    Hoy, Jennifer
    Agius, Paul
    Iser, David
    O'reilly, Mark
    Sasadeusz, Joe
    Stoove, Mark
    Roney, Janine
    Moore, Richard
    Bk, Tee
    Medland, Nick
    Fairley, Christopher
    Gane, Edward
    Matthews, Gail
    Prins, Maria
    Hellard, Margaret
    Doyle, Joseph
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E204 - E204
  • [30] How important is HIV therapy for preventing liver fibrosis progression in HIV-HCV-coinfected individuals?
    Rockstroh, Juergen Kurt
    ANTIVIRAL THERAPY, 2012, 17 (07) : 1223 - 1225
12345